Delving into the Latest Updates on Novo Nordisk Pharma Korea Ltd. with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	1
神经系统疾病	1

排名前五的药物类型	数量

重组凝血因子	1

排名前五的靶点	数量

F10(凝血因子X)	1

关联

1

项与 Novo Nordisk Pharma Korea Ltd. 相关的药物

Eptacog alfa(Novo Nordisk A/S)

依他凝血素α

靶点

F10

作用机制

F10刺激剂

在研机构

Novo Nordisk A/S [+3]

原研机构

Novo Nordisk A/S

在研适应症

常染色体显性遗传性血小板减少症 [+9]

非在研适应症

纤维化 [+4]

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期1996-02-23

100 项与 Novo Nordisk Pharma Korea Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Novo Nordisk Pharma Korea Ltd. 相关的专利（医药）

登录后查看更多信息

7

项与 Novo Nordisk Pharma Korea Ltd. 相关的文献（医药）

2024-09-30·Diabetes & Metabolism Journal

Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus

Article

作者: Oh, Tae Keun ; Chun, Sung Wan ; Jung, Sungeun ; Jeong, Jin Sook ; Lee, Won-Young ; Ahn, Yu-Bae ; Jang, Hak Chul ; Bae, Boram ; Kang, Shinae ; Dahaoui, Amine

Background: This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp.Methods: This was a multicenter, retrospective, observational study comprising two 26-week treatment periods, before and after switching to IDegAsp, respectively. Korean adults with uncontrolled T2DM treated with basal or premix insulin (±oral antidiabetic drugs) were enrolled. The primary objective was to compare the degree of glycosylated hemoglobin (HbA1c) change in each 26-week observation period. The analyses included changes in HbA1c, fasting plasma glucose (FPG), body weight, proportion of participants achieving HbA1c <7.0%, hypoglycemic events, and total daily insulin dose (ClinicalTrials.gov, number NCT04656106).Results: In total, 196 adults (mean age, 65.95 years; mean T2DM duration, 18.99 years) were analyzed. The change in both HbA1c and FPG were significantly different between the pre-switching and the post-switching period (0.28% vs. –0.51%, P<0.001; 5.21 mg/dL vs. –23.10 mg/dL, P=0.005), respectively. After switching, the rate of achieving HbA1c <7.0% was significantly improved (5.10% at baseline vs. 11.22% with IDegAsp, P=0.012). No significant differences (before vs. after switching) were observed in body weight change, and total daily insulin dose. The rates of overall and severe hypoglycemia were similar in the two periods.Conclusion: In real-world clinical practice in Korea, the change of insulin regimen to IDegAsp was associated with an improvement in glycemic control without increase of hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled with basal or premix insulin.

2024-02-01·Diabetes Therapy

Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes

Article

作者: Kim, Sin Gon ; Lee, Byung-Wan ; Dahaoui, Amine ; Lim, Hyo Jin ; Yu, Jae Myung ; Ko, Seung-Hyun ; Jeong, Jin Sook ; Cho, Young Min ; Lim, Soo

INTRODUCTIONGlucagon-like peptide-1 receptor agonists are well-established type 2 diabetes (T2D) treatments. As variations among populations and culture might influence treatment effects, this post hoc analysis evaluates the efficacy and safety of once-weekly (OW) semaglutide in a Korean population.METHODSKorean adults with T2D inadequately controlled on metformin included in a 30-week, phase 3a, international, multicentre trial (NCT03061214) compared OW subcutaneous semaglutide (0.5 mg and 1.0 mg) with once-daily sitagliptin (100 mg). Key endpoints included change in glycated haemoglobin (HbA_1c) and body weight; additional endpoints assessed proportions of participants reaching targets of HbA_1c < 7.0% and ≤ 6.5%, ≥ 5% weight loss, and a composite endpoint of HbA_1c < 7.0% without severe/blood glucose-confirmed symptomatic hypoglycaemia and no weight gain.RESULTSKorean participants (n = 110) showed a greater reduction in HbA_1c and body weight with semaglutide 0.5 mg (-1.6%, -2.7 kg) and 1.0 mg (-1.8%, -4.8 kg) versus sitagliptin (-0.9%, 0.5 kg). HbA_1c targets of < 7.0% and ≤ 6.5% were achieved by more participants treated with semaglutide 0.5 mg (80.0% and 60.0%, respectively) and 1.0 mg (87.5% and 67.5%, respectively) versus sitagliptin (54.3% and 25.7%, respectively); ≥ 5% weight loss was observed in 42.9% and 65.0% of participants treated with semaglutide 0.5 mg and 1.0 mg versus 0.0% with sitagliptin. The composite endpoint was achieved by 71.4%, 77.5%, and 31.4% of the population in the semaglutide 0.5 mg, 1.0 mg, and sitagliptin group, respectively. No new safety concerns were observed.CONCLUSIONThis analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D.CLINICAL TRIAL REGISTRATION NUMBERNCT03061214.

2023-10-01·Diabetes therapy : research, treatment and education of diabetes and related disorders

Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study.

Article

作者: Cho, Ho Chan ; Lim, Hyo Jin ; Lee, Byung Wan ; Jang, Hak Chul ; Dahaoui, Amine ; Lee, Eun Young ; Min, KyungWan ; Jeong, Jin Sook ; Ahn, Kyu Jeung

INTRODUCTIONTo investigate the safety and effectiveness of insulin degludec (IDeg) in a real-world population of Korean patients with diabetes requiring insulin therapy.METHODSThis was a multicenter, prospective, single-arm, open-label, non-interventional study. Patients aged ≥ 12 months and treated with previous glucose-lowering medications were eligible to switch to IDeg. The primary endpoint was the incidence of adverse events (AEs), and the secondary endpoints were changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose (PPG), and target HbA1c < 7.0%.RESULTSIn total, 3225 and 2450 patients were included in the safety analysis set (SAS) and effectiveness analysis set (EAS), respectively. The mean baseline HbA1c and duration of diabetes were 9.4% and 13.0 years, respectively. Adverse events were reported in 740 patients (22.9%); the majority were mild and resolved. Significant improvements were observed in HbA1c, FPG, and PPG at week 26 (all p < 0.0001). The target of HbA1c < 7% was achieved in 22.2% of patients at week 26.CONCLUSIONIn real-world clinical practice, 26 weeks of IDeg treatment resulted in significant reductions in glycemic parameters with a low incidence of AEs in Korean patients with diabetes. No new safety signals were observed.CLINICAL TRIALS REGISTRY AND REGISTRATION NUMBERThis trial is registered under ClinicalTrials.gov (NCT02779413) and the universal trial number is [U1111-1176-2287].

100 项与 Novo Nordisk Pharma Korea Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Novo Nordisk Pharma Korea Ltd. 相关的转化医学

登录后查看更多信息